{"authors": [["Jones", "Alan", "A", "Department of Clinical Biochemistry and Immunology, Birmingham, United Kingdom."], ["Peers", "Kate", "K", "Department of Clinical Biochemistry and Immunology, Birmingham, United Kingdom."], ["Ramachandran", "Sud", "S", "Department of Clinical Biochemistry and Immunology, Birmingham, United Kingdom."], ["Syed", "Ateeq", "A", "Department of Diabetes/Endocrinology, Birmingham, United Kingdom."]], "text": "", "id": "29365947", "date": "2017-08-12", "title": "A comparison of the efficacy and tolerability of the PCSK9 inhibitors, Alirocumab and evolocumab, in routine lipid clinic practice.", "doi": "10.1016/j.atherosclerosis.2017.06.802", "journal": ["Atherosclerosis", "Atherosclerosis"]}